TARA 外汇新闻

Protara Therapeutics, Inc. (TARA) announced Friday that it has reached alignment with the U.S. Food and Drug Administration (FDA) on a registrational path forward for intravenous (IV) Choline Chloride, an investigational phospholipid substrate replacement.